151 related articles for article (PubMed ID: 29755792)
1. Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.
Ahmed OA; Safwat E; Khalifa MO; Elshafie AI; Fouad MHA; Salama MM; Naguib GG; Eltabbakh MM; Sherief AF; Abd-Elsalam S
Int J Hepatol; 2018; 2018():9616234. PubMed ID: 29755792
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
3. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.
Ahmed OA; Elsebaey MA; Fouad MHA; Elkadeem M; Badawi R; Khayyal A; Soliman S; Negm MS; Abd-Elsalam S
Infect Disord Drug Targets; 2020; 20(3):389-395. PubMed ID: 30569878
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
[TBL] [Abstract][Full Text] [Related]
7. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
El-Nahaas SM; Fouad R; Elsharkawy A; Khairy M; Elhossary W; Anwar I; Abdellatif Z; Maher RM; Bekheet N; Esmat G
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1194-1199. PubMed ID: 30096091
[TBL] [Abstract][Full Text] [Related]
8. Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.
Abdel-Aziz AM; Ibrahim MA; El-Sheikh AA; Kamel MY; Zenhom NM; Abdel-Raheim S; Abdelhaleem H
J Clin Exp Hepatol; 2018 Mar; 8(1):15-22. PubMed ID: 29743792
[TBL] [Abstract][Full Text] [Related]
9. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Hézode C; Lebray P; De Ledinghen V; Zoulim F; Di Martino V; Boyer N; Larrey D; Botta-Fridlund D; Silvain C; Fontaine H; D'Alteroche L; Leroy V; Bourliere M; Hubert-Fouchard I; Guyader D; Rosa I; Nguyen-Khac E; Fedchuk L; Akremi R; Bennai Y; Filipovics A; Zhao Y; Bronowicki JP
Liver Int; 2017 Sep; 37(9):1314-1324. PubMed ID: 28177199
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
Lashen SA; Shamseya MM; Madkour MA; Aboufarrag GA
Liver Int; 2019 May; 39(5):835-843. PubMed ID: 30549417
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.
Ibrahim Mohammed Ebid AH; Ashraf Ahmed O; Hassan Agwa S; Mohamed Abdel-Motaleb S; Mohamed Elsawy A; Hagag RS
J Clin Pharm Ther; 2020 Jun; 45(3):539-546. PubMed ID: 31889322
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Wyles DL; Ruane PJ; Sulkowski MS; Dieterich D; Luetkemeyer A; Morgan TR; Sherman KE; Dretler R; Fishbein D; Gathe JC; Henn S; Hinestrosa F; Huynh C; McDonald C; Mills A; Overton ET; Ramgopal M; Rashbaum B; Ray G; Scarsella A; Yozviak J; McPhee F; Liu Z; Hughes E; Yin PD; Noviello S; Ackerman P;
N Engl J Med; 2015 Aug; 373(8):714-25. PubMed ID: 26196502
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]